• DiscoveryProbe™ FDA-approved Drug Library: High-Content S...

  2025-11-04

  The DiscoveryProbe™ FDA-approved Drug Library enables high-throughput screening (HTS) and drug repositioning using 2,320 clinically validated compounds. This resource accelerates pharmacological target identification and advances research in oncology, neurodegeneration, and rare diseases.

• DiscoveryProbe FDA-approved Drug Library: Transforming Hi...

  2025-11-03

  The DiscoveryProbe™ FDA-approved Drug Library empowers researchers with a clinically relevant, high-content screening compound collection purpose-built for rapid drug repositioning and target identification. Streamline assay setup, enhance reproducibility, and unlock new therapeutic insights across cancer, neurodegenerative, and signal pathway research with this rigorously curated, FDA-approved bioactive compound library.

• GSK343: Redefining EZH2 Inhibition for Advanced Epigeneti...

  2025-11-02

  Explore the unique potential of GSK343, a selective EZH2 inhibitor, in unraveling the intersection of histone methylation, DNA repair, and telomerase regulation. Discover how this cell-permeable tool empowers next-generation epigenetic cancer research through precise PRC2 pathway modulation.

• DiscoveryProbe FDA-approved Drug Library: Accelerating Hi...

  2025-11-01

  The DiscoveryProbe™ FDA-approved Drug Library revolutionizes drug discovery workflows with a rigorously curated collection of 2,320 pre-dissolved, clinically approved compounds. Its ready-to-screen format enables researchers to rapidly identify novel therapeutic targets, streamline drug repositioning, and tackle complex pharmacological questions in cancer, neurodegenerative disorders, and beyond.

• DiscoveryProbe™ FDA-approved Drug Library: Next-Gen Scree...

  2025-10-31

  Explore how the DiscoveryProbe FDA-approved Drug Library revolutionizes high-throughput screening for viral protease inhibitors and pathway regulation. This article offers a unique, in-depth perspective on leveraging FDA-approved compound libraries for antiviral research, drug repositioning, and mechanistic discovery.

• GSK343: Selective EZH2 Inhibitor for Precision Epigenetic...

  2025-10-30

  GSK343 is a potent, cell-permeable, and highly selective EZH2 inhibitor optimized for dissecting histone H3K27 trimethylation in cancer and stem cell models. As a SAM-competitive methyltransferase inhibitor, GSK343 enables precise modulation of the polycomb repressive complex 2 (PRC2) pathway, supporting advanced epigenetic cancer research and workflow integration.

• Beyond the Hit: Mechanistic Insight and Strategic Acceler...

  2025-10-29

  Translational researchers face unprecedented challenges in bridging mechanistic understanding with actionable therapeutic discovery. This thought-leadership article delivers an advanced, evidence-driven perspective on leveraging the DiscoveryProbe™ FDA-approved Drug Library for high-throughput and high-content screening, drug repositioning, and pharmacological target identification—going beyond standard product narratives to chart the next frontier in cancer and neurodegenerative disease research.

• From Mechanism to Medicine: Strategic High-Throughput Scr...

  2025-10-28

  Translational researchers face the dual challenge of unraveling complex disease mechanisms and delivering actionable therapeutic solutions. This thought-leadership article explores how the DiscoveryProbe™ FDA-approved Drug Library (L1021) empowers next-generation high-throughput and high-content screening. By integrating mechanistic insights from cutting-edge research—such as the repurposing of drugs to disrupt 14-3-3 protein-BAD interactions in colorectal cancer—this article provides strategic, evidence-based guidance for translational teams. Discover how a comprehensive FDA-approved bioactive compound library positions your research at the intersection of scientific rigor, clinical relevance, and competitive innovation.

• Maximizing Discovery with the DiscoveryProbe FDA-approved...

  2025-10-27

  The DiscoveryProbe™ FDA-approved Drug Library accelerates translational research by enabling rapid, robust high-throughput and high-content screening with 2,320 clinically validated compounds. Its ready-to-use format supports drug repositioning, target identification, and mechanistic studies across oncology, neurodegeneration, and rare disease landscapes, empowering researchers to move seamlessly from bench to breakthrough.

• DiscoveryProbe FDA-approved Drug Library: Optimizing High...

  2025-10-26

  The DiscoveryProbe™ FDA-approved Drug Library empowers translational researchers to accelerate drug repositioning, target identification, and mechanistic discovery using a rigorously curated, ready-to-screen compound collection. Its clinically vetted diversity, pre-dissolved convenience, and compatibility with high-throughput and high-content workflows set a new standard for streamlining pharmacological innovation across oncology, neurodegeneration, and beyond.

• DiscoveryProbe FDA-approved Drug Library: Transforming Hi...

  2025-10-25

  The DiscoveryProbe™ FDA-approved Drug Library empowers translational teams to accelerate drug repositioning, target identification, and mechanistic discovery using 2,320 clinically relevant compounds. Its versatility in high-throughput and high-content screening unlocks rapid, data-driven insights across oncology, neurodegeneration, and emerging infectious diseases. Researchers gain a powerful edge with ready-to-screen, stability-optimized solutions and proven application in breakthrough studies.

• From Mechanism to Medicine: Strategic Acceleration of Tra...

  2025-10-24

  Translational researchers face mounting pressure to bridge mechanistic insight with actionable therapeutic innovation. This thought-leadership article synthesizes the latest advances in high-throughput screening (HTS), drug repositioning, and mechanistic biology, using the DiscoveryProbe™ FDA-approved Drug Library as a central tool. We analyze the biological rationale for leveraging clinically validated bioactive compounds, showcase experimental validation in neuroepigenetic disease, compare competitive screening platforms, and outline a visionary roadmap for accelerating target identification and clinical translation—particularly for challenging indications such as cancer and neurodegenerative disorders.

• DiscoveryProbe™ FDA-approved Drug Library: Transforming C...

  2025-10-23

  Explore how the DiscoveryProbe™ FDA-approved Drug Library enables unprecedented cell-based drug repositioning and pharmacological target identification. This article reveals advanced screening strategies, integrating recent mechanistic breakthroughs for translational biomedical research.

• DiscoveryProbe FDA-approved Drug Library: Transforming Hi...

  2025-10-22

  The DiscoveryProbe™ FDA-approved Drug Library accelerates translational research with a ready-to-screen collection of 2,320 clinically validated compounds. Its versatility in high-throughput and high-content screening empowers drug repositioning, target identification, and advanced disease modeling across oncology, neurology, and rare diseases.

• GDC-0941: A Selective PI3K Inhibitor for Translational On...

  2025-10-21

  GDC-0941 is a highly selective class I PI3 kinase inhibitor optimized for robust PI3K/Akt pathway inhibition, including in trastuzumab-resistant HER2-amplified cancer models. This guide details advanced experimental workflows, troubleshooting insights, and comparative advantages, empowering researchers to maximize the translational impact of GDC-0941 across in vitro and in vivo oncology studies.

11192 records 1/747 page Next 12345 下5页 Last page